Glivec Research Today is a free monthly online journal that collates and summarizes the latest research about Glivec, including details on gleevec, imatinib, cancer, treatment, side-effects.

Volume 4 (2007), Issue 1 (January)

1. The platelet-derived growth factor receptor alpha is destabilized by geldanamycins in cancer cells.
   J Biol Chem, 282(1): 445-53. [Abstract] [Full-text]
2. Emerging role of platelet-derived growth factor receptor-beta inhibition in radioimmunotherapy of experimental pancreatic cancer.
   Clin Cancer Res, 13(1): 299-306. [Abstract] [Full-text]
3. Clinical and in vitro studies of imatinib in advanced carcinoid tumors.
   Clin Cancer Res, 13(1): 234-40. [Abstract] [Full-text]
4. Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors.
   Clin Cancer Res, 13(1): 170-81. [Abstract] [Full-text]
5. Fusion tyrosine kinases: a result and cause of genomic instability.
   Oncogene, 26(1): 11-20. [Abstract] [Full-text]
6. Comparative proteomic analysis of chronic myelogenous leukemia cells: inside the mechanism of imatinib resistance.
   J Proteome Res, 6(1): 367-75. [Abstract] [Full-text]
7. Molecular Pathogenesis and Therapy of Polycythemia Induced in Mice by JAK2 V617F.
   PLoS ONE, 1: e18. [Abstract] [Full-text]
8. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation.
   Blood, 109(2): 500-2. [Abstract] [Full-text]
9. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure.
   Blood, 109(2): 497-9. [Abstract] [Full-text]
10. Livedoid skin reaction probably due to imatinib therapy.
    Ann Pharmacother, 41(1): 148-52. [Abstract] [Full-text]
11. Extramedullary disease and targeted therapies for hematological malignancies--is the association real?
    Ann Oncol, 18(1): 7-12. [Abstract] [Full-text]
12. Population-based incidence and survival of gastrointestinal stromal tumours (GIST) in Girona, Spain.
    Eur J Cancer, 43(1): 144-8. [Abstract] [Full-text]
13. Interstitial cells of Cajal in health and disease. Part II: ICC and gastrointestinal stromal tumours.
    Histopathology, 50(2): 190-202. [Abstract] [Full-text]
14. Reduced-intensity conditioning followed by T-cell depleted allogeneic stem cell transplantation for patients with chronic myeloid leukaemia and minimal residual disease at the time of transplant: high risk of molecular relapse.
    Br J Haematol, 136(1): 127-30. [Abstract] [Full-text]
15. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.
    Cancer, 109(2): 248-55. [Abstract] [Full-text]
16. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.
    Oncologist, 12(1): 107-13. [Abstract] [Full-text]
17. Economic evaluations of leukemia: A review of the literature.
    Int J Technol Assess Health Care, 23(1): 43-53. [Abstract] [Full-text]
18. Beta1 integrin mediated adhesion increases Bim protein degradation and contributes to drug resistance in leukaemia cells.
    Br J Haematol, 136(2): 269-75. [Abstract] [Full-text]
19. KIT-negative undifferentiated endometrial sarcoma with the amplified epidermal growth factor receptor gene showing a temporary response to imatinib mesylate.
    Ann Diagn Pathol, 11(1): 49-54. [Abstract] [Full-text]
20. KIT mutations in GIST.
    Curr Opin Genet Dev, 17(1): 3-7. [Abstract] [Full-text]
21. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments.
    Ann Surg Oncol, 14(2): 942-53. [Abstract] [Full-text]
22. Surgical Management After Neoadjuvant Imatinib Therapy in Gastrointestinal Stromal Tumours (GISTs) with Respect to Imatinib Resistance Caused by Secondary KIT Mutations.
    Ann Surg Oncol, 14(2): 526-32. [Abstract] [Full-text]
23. Imatinib mesylate potentiates topotecan antitumor activity in rhabdomyosarcoma preclinical models.
    Int J Cancer, 120(5): 1141-9. [Abstract] [Full-text]
24. Severe paraneoplastic hypoglycemia in a patient with a gastrointestinal stromal tumor with an exon 9 mutation: a case report.
    BMC Cancer, 7: 13. [Abstract] [Full-text]
25. Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: A phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Eur J Cancer, 43(2): 308-15. [Abstract] [Full-text]
26. Optimal initial therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase.
    Curr Opin Hematol, 14(2): 138-44. [Abstract] [Full-text]
27. Simultaneous determination of AMN107 and Imatinib (Gleevec, Glivec, STI571) in cultured tumour cells using an isocratic high-performance liquid chromatography procedure with UV detection.
    J Chromatogr B Analyt Technol Biomed Life Sci, 846(1): 341-5. [Abstract] [Full-text]
28. Autologous stem cell transplantation in chronic myeloid leukaemia: a meta-analysis of six randomized trials.
    Cancer Treat Rev, 33(1): 39-47. [Abstract] [Full-text]
29. Cyclodextrin/imatinib complexation: Binding mode and charge dependent stabilities.
    Eur J Pharm Sci, 30(2): 167-74. [Abstract] [Full-text]
30. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.
    Arthritis Rheum, 56(1): 311-22. [Abstract] [Full-text]
31. Clinical Features of Hypereosinophilic Syndrome: FIP1L1-PDGFRA Fusion Gene-Positive Disease is a Distinct Clinical Entity with Myeloproliferative Features and a Poor Response to Corticosteroid.
    Int J Hematol, 85(1): 5-10. [Abstract] [Full-text]
32. Systemic treatment options for patients with refractory adult-type sarcoma beyond anthracyclines.
    Anticancer Drugs, 18(3): 245-54. [Abstract] [Full-text]
33. Leukaemic infiltration of the mandible in a young girl.
    Int J Paediatr Dent, 17(2): 145-50. [Abstract] [Full-text]

© 2004-2008 Glivec Research Today. All Rights Reserved.